MRD-negative Status Linked With Better Survival in Multiple Myeloma

Share this content:
Minimal residual disease-negative status among patients with newly-diagnosed multiple myeloma after treatment may be associated with long-term survival.
Minimal residual disease-negative status among patients with newly-diagnosed multiple myeloma after treatment may be associated with long-term survival.

Minimal residual disease (MRD)-negative status among patients with newly-diagnosed multiple myeloma after treatment may be associated with long-term survival, according to a study published in JAMA Oncology.1

Researchers led by Nikhil Munshi, MD, of the Dana-Farber Cancer Institute in Boston, MA, evaluated 21 studies through Medline, which provided data on the impact of MRD status on progression-free and overall survival.

Information on patient characteristics, treatment, MRD assessment, and outcomes, were gathered. Data were adjusted to allow for different proportions of patients with MRD across the studies.

There were 12 studies with data on impact of MRD on overall survival, and 14 for progression-free survival. MRD-negative status was associated with better progression-free survival, particularly in studies of patients who had achieved conventional complete response.

RELATED: KRd Improves QoL vs Rd Alone in Multiple Myeloma

Overall survival was favorable among MRD-negative patients, as well as among patients with complete response.

Reference

  1. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2016 Sep 15. doi:10.1001/jamaoncol.2016.3160 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters